HC Wainwright Reiterates Buy Rating for Aemetis (NASDAQ:AMTX)

HC Wainwright restated their buy rating on shares of Aemetis (NASDAQ:AMTX) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $28.00 target price on the specialty chemicals company’s stock.

AMTX has been the topic of several other reports. StockNews.com raised Aemetis to a “sell” rating in a report on Wednesday, July 31st. Ascendiant Capital Markets dropped their price objective on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Truist Financial reissued a “hold” rating and issued a $3.50 price objective (down from $4.00) on shares of Aemetis in a report on Wednesday, July 31st. Finally, UBS Group dropped their price objective on Aemetis from $8.25 to $7.75 and set a “buy” rating on the stock in a report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Aemetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.95.

Aemetis Stock Down 1.3 %

Aemetis stock opened at $3.78 on Friday. The firm has a market cap of $188.00 million, a price-to-earnings ratio of -1.67 and a beta of 1.23. Aemetis has a 52 week low of $2.10 and a 52 week high of $7.03. The business’s 50-day moving average price is $2.83 and its 200 day moving average price is $3.05.

Aemetis (NASDAQ:AMTX) last posted its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.09. The company had revenue of $81.44 million for the quarter, compared to analyst estimates of $77.79 million. During the same period last year, the business earned ($0.59) earnings per share. Equities analysts expect that Aemetis will post -2.1 EPS for the current year.

Institutional Trading of Aemetis

A number of institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Aemetis during the first quarter worth approximately $60,000. State Board of Administration of Florida Retirement System purchased a new position in Aemetis during the first quarter worth approximately $84,000. FMR LLC lifted its position in Aemetis by 68.2% during the third quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock worth $52,000 after buying an additional 9,137 shares in the last quarter. Hutchinson Capital Management CA purchased a new position in Aemetis during the second quarter worth approximately $70,000. Finally, Barclays PLC lifted its position in Aemetis by 274.6% during the third quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock worth $109,000 after buying an additional 34,816 shares in the last quarter. 27.02% of the stock is owned by institutional investors and hedge funds.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.